Nevertheless, 18F-FDG PET data will be acquired for clinical work-up in all patients (as inclusion criteria) and most patients will also receive lumbar punctions to determine cerebrospinal fluid levels of Aβ42/Aβ40 and total tau to exclude or confirm AD. This evidence concerns the gene MAPT and Alzheimer disease.